At a glance
ClinicalIndex Comparison RecordN/ACompleted· 45 enrolled
Drug / intervention
Nucleus CI532 cochlear implantdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Investigation of the Nucleus® CI532 Cochlear Implant
In Brief
A clinical study evaluating Nucleus CI532 cochlear implant for Hearing Loss. Completed, enrolled 45 participants across 8 sites in 4 countries.
Detailed Summary
The aim of this study is to investigate the clinical benefit for patients implanted with the Nucleus® CI532 cochlear implant and to demonstrate the atraumatic nature of the electrode design. Nucleus® CI532 has a pre-curved, perimodiolar array, the EA32, which is introduced into the cochlea through a straightening sheath.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHearing Loss
CountriesAustralia, France, Germany, Spain
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartApr 2015
Primary CompletionJul 2016
TodayJul 2026
First PostedMar 19, 2015
Enrollment StartApr 1, 2015
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.3 years ago
Interventions
Nucleus CI532 cochlear implantdevice